2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
Jeffrey Weber, MD, selects the most important presentations on skin cancers from the 2016 American Society of Clinical Oncology Annual Meeting.

Skin Cancers

Binimetinib significantly improved PFS and response rates in NRAS-mutant melanoma, particularly in patients who received prior immunotherapy.

Released: June 10, 2016

Median OS not reached for pembrolizumab at median follow-up of 23 months, with continuing durable responses and favorable safety profile.

Released: June 13, 2016

Pembrolizumab plus ipilimumab appear to be well tolerated and produced robust, durable responses in patients with advanced melanoma.

Released: June 14, 2016

Small phase Ib trial demonstrated that combination treatment with T-VEC plus pembrolizumab in advanced unresectable melanoma yields ORR of 57% and CR of 24%.

Released: June 6, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings